题名

結合中西醫理論探討嚴重特殊傳染性肺炎的病程進展及治療展望

并列篇名

Exploring the progression and treatment prospects of Coronavirus disease 2019 (COVID-19) with the integration of Traditional Chinese and Western Medicine

DOI

10.6516/TJTCM.202006/SP_23.0008

作者

黃靖鈞(Ching-Chun Huang)；吳孟珊(Meng-Shan Wu)；陳忠仁(Chung-Jen Chen)

关键词

新冠肺炎 ； 新型冠狀病毒 ； 衛氣營血 ； COVID-19 ； SARS-CoV-2 ； Wei, Qi, Ying, and Xue

期刊名称

中醫藥研究論叢

卷期/出版年月

23卷特刊（2020 / 06 / 30）

页次

105 - 127

内容语文

繁體中文
中文摘要

新冠肺炎Coronavirus disease 2019（COVID-19）是由一種新型冠狀病毒SARS-CoV-2所引起的疾病，已成為世界各國目前迫切需要解決的醫療問題。對於COVID-19，整合中西醫的相關研究，運用中醫理論來進行分析探討中醫藥所能扮演的角色是本篇文章的核心價值。本文對於COVID-19的論述主要根據近期發表的研究文獻，從流行病學、病毒學、臨床症狀和西醫治療概略說明，再進入中醫對此疾病的認識，依照病程輕重結合衛氣營血的傳變推論病因病機，並運用現代醫學的研究成果加強以上中醫的論述。衛分屬COVID-19發作初期的免疫反應；氣分屬正邪相爭達免疫高峰期；營分屬血管內皮功能異常；血分屬凝血障礙造成血栓或瀰漫性血管內凝血。最後在文獻實證的基礎下，探討中醫治療用方，病程在輕、中症屬衛、氣分，可選用銀翹散、桑菊飲或麻杏甘石湯，病程進入重危症屬營、血分，治療以西醫為主、中醫為輔，可使用安宮牛黃丸、生脈散或犀角地黃湯。期待中西醫學的合作，有助於提升新冠肺炎的治療效果及預後。
英文摘要

Coronavirus disease 2019 (COVID-19) is a disease caused by a new coronavirus SARS-CoV-2, and has become an urgent medical problem needed to be resolved all over the world. The core value of this article was to integrate relevant research on Traditional Chinese medicine (TCM) and Western medicine (WM), and analyzed as well as explored the role that TCM can play by the theory of TCM. The thematic discussion about COVID-19 was mainly based on the recently published research literature. The article started from the general description of epidemiology, virology, clinical symptoms and WM treatment. Then, we discussed the viewpoint of TCM on COVID-19 and inferred the etiology and pathogenesis according to the severity of the progress of COVID-19 and the transmission of Wei, Qi, Ying, and Xue. In addition, we took advantage of modern medical research to strengthen the above paragraph. We described Wei as part of the immune response in the early stage, Qi as part of struggling between the vital energy and the pathogenic factor to reach the peak of immunity, Ying as part of vascular endothelial dysfunction and Xue as part of blood coagulation disorder such as thrombosis or diffuse intravascular coagulation (DIC). Finally, on the basis of evidence-based literature, we discussed the prescriptions of TCM. The mild and moderate stages of the disease could be defined as Wei and Qi, which could be prescribed Yin Qiao San, Sang Ju Yin or Ma Xing Gan Shi Tang. In the critical stage of the disease which could be defined as Ying and Xue, we could use An Gong Niu Huang Wan, Sheng Mai San or Xi Jiao Di Huang Tang for adjuvant therapy. It is expected that the cooperation between TCM and WM will help to improve the therapeutic effect and the prognosis of COVID-19.
主题分类 醫藥衛生 > 中醫藥學
醫藥衛生 > 藥理醫學
参考文献
  1. Interview with David Juurlink. Coronavirus (COVID-19) update: chloroquine/hydroxyl chloroquine and azithromycin. JAMA. March 24, 2020. Accessed April 3, 2020. https://edhubama-assn.org/jn-learning/audio-player/18337225
  2. ClinicalTrials.gov. Accessed March 18, 2020. https://clinicaltrials.gov/
  3. https://www.entnet.org/content/coronavirus-disease-2019-resources (Accessed on March 23, 2020).
  4. （明）吳又可,（明）鄭重光(1985).溫疫論補證.台北:新文豐出版社.
  5. （清）吳瑭,（清）李一宏,（清）黃香玲(2012).溫病條辨.台北:志遠書局.
  6. （清）葉天士(2012).葉天士醫學全書.太原:山西科學技術出版社.
  7. （隋）巢元方(2002).諸病源候論.台北:集文出版社.
  8. Al-Bari, MAA(2017).Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.Pharmacol Res Perspect,5(1),e00293.
  9. Alramthan, A,Aldaraji, W(2020).A case of COVID 19 presenting in clinical picture resembling chilblains disease. First report from the Middle East.Clin Exp Dermatol
  10. Al-Tawfiq, JA,Al-Homoud, AH,Memish, ZA(2020).Remdesivir as a possible therapeutic option for the COVID-19.Travel medicine and infectious disease
  11. Armstrong, SM,Mubareka, S,Lee, WL(2013).The lung microvascular endothelium as a therapeutic target in severe influenza.Antiviral research,99(2),113-118.
  12. Bahl, P,Doolan, C,de Silva, C,Chughtai, AA,Bourouiba, L,MacIntyre, CR(2020).Airborne or droplet precautions for health workers treating COVID-19?.The Journal of infectious diseases
  13. Benias, PC,Wells, RG,Sackey-Aboagye, B,Klavan, H,Reidy, J,Buonocore, D,Miranda, M,Kornacki, S,Wayne, M,Carr-Locke, DL,Theise, ND(2018).Structure and distribution of an unrecognized interstitium in human tissues.Scientific reports,8(1),1-8.
  14. Bourouiba, L(2020).Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19.JAMA
  15. Chan, JF,Yuan, S,Kok, KH,To, KK,Chu, H,Yang, J,Xing, F,Liu, J,Yip, CC,Poon, RW,Tsoi, HW,Lo, SK,Chan, KH,Poon, VK,Chan, WM,Ip, JD,Cai, JP,Cheng, VC,Chen, H,Hui, CK,Yuen, KY(2020).A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.The Lancet,395(10223),514.
  16. Chan, KW,Wong, VT,Tang, SCW(2020).COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease.The American journal of Chinese medicine,48(3),1-26.
  17. Chen, CJ,Kwong, PC,Lin, YC(2020).A strategy of traditional Chinese medicine against COVID linking current basic research and ancient medicine texts.International Journal of Complementary & Alternative Medicine,13(2),79-81.
  18. Chen, J.,LIU, D.,LIU, L.,LIU, P.,XU, Q.,XIA, L.,QIAN, Z.(2020).A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19).Journal of Zhejiang University (Medical Science),49(1),0-0.
  19. Chen, N,Zhou, M,Dong, X,Qu, J,Gong, F,Han, Y,Qiu, Y,Wang, J,Liu, Y,Wei, Y,Xia, J,Yu, T,Zhang, X,Zhang, L(2020).Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet,395(10223),507.
  20. Cheung, KS,Hung, IF,Chan, PP,Lung, KC,Tso, E,Liu, R,Ng, YY,Chu, MY,Chung, TW,Tam, AR,Yip, CC,Leung, KH,YimFong, Fung, A,Zhang, RR,Lin, Y,Cheng, HM,Zhang, AJ,To, KK,Chan, KH,Yuen, KY,Leung, WK(2020).Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis.Gastroenterology
  21. Colavita, F,Lapa, D,Carletti, F,Lalle, E,Bordi, L,Marsella, P,Nicastri, E,Bevilacqua, N,Giancola, ML,Corpolongo, A,Ippolito, G,Capobianchi, MR,Castilletti, C(2020).SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection.Ann Intern Med
  22. Cui, HT,Li, YT,Guo, LY,Liu, XG,Wang, LS,Jia, JW,Liao, JB,Miao, J,Zhang, ZY,Wang, L,Wang, HW,Wen, BW(2020).Traditional Chinese medicine for treatment of coronavirus disease 2019: a review.Traditional Medicine Research,5(2),65-73.
  23. de Masson, A,Bouaziz, JD,Sulimovic, L,Cassius, C,Jachiet, M,Ionescu, MA,Rybojad, M,Bagot, M,Duong, TA,SNDV (French Union of Dermatologists-Venereologists)(2020).Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France.J Am Acad Dermatol
  24. Devaux, CA,Rolain, JM,Colson, P,Raoult, D(2020).New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?.International journal of antimicrobial agents
  25. Eng, YS,Lee, CH,Lee, WC,Huang, CC,Chang, JS(2019).Unraveling the Molecular Mechanism of Traditional Chinese Medicine: Formulas Against Acute Airway Viral Infections as Examples.Molecules,24(3505),1-29.
  26. Galván Casas, C,Català, A,Carretero Hernández, G,Rodríguez-Jiménez, P,Fernández Nieto, D,Rodríguez-Villa Lario, A,Navarro Fernández, I,Ruiz-Villaverde, R,Falkenhain, D,Llamas Velasco, M,García-Gavín, J,Baniandrés, O,González-Cruz, C,Morillas-Lahuerta, V,Cubiró, X,Figueras Nart, I,Selda-Enriquez, G,Romaní, J,Fustà-Novell, X,Melian-Olivera, A,Roncero Riesco, M,Burgos-Blasco, P,Sola Ortigosa, J,Feito Rodriguez, M,García-Doval, I(2020).Classification of the cutaneous manifestations of COVID 19: a rapid prospective nationwide consensus study in Spain with 375 cases.Br J Dermatol
  27. Gao, J,Tian, Z,Yang, X(2020).Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.Biosci Trends,14(1),72-73.
  28. Gautret, P.,Lagier, J. C.,Parola, P.,Meddeb, L.,Mailhe, M.,Doudier, B.,Honoré, S.(2020).Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.International journal of antimicrobial agents
  29. Geleris, J,Sun, Y,Platt, J,Zucker, J,Baldwin, M,Hripcsak, G,Labella, A,Manson, D,Kubin, C,Barr, RG,Sobieszczyk, ME,Schluger, NW(2020).Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.The New England journal of medicine
  30. Giacomelli, A,Pezzati, L,Conti, F,Bernacchia, D,Siano, M,Oreni, L,Rusconi, S,Gervasoni, C,Ridolfo, AL,Rizzardini, G,Antinori, S,Galli, M(2020).Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study.Clin Infect Dis
  31. Goyal, P,Choi, JJ,Pinheiro, LC,Schenck, EJ,Chen, R,Jabri, A,Satlin, MJ,Campion, TR, Jr,Nahid, M,Ringel, JB,Hoffman, KL,Alshak, MN,Li, HA,Wehmeyer, GT,Rajan, M,Reshetnyak, E,Hupert, N,Horn, EM,Martinez, FJ,Gulick, RM,Safford, MM(2020).Clinical Characteristics of Covid-19 in New York City.New England Journal of Medicine
  32. Grein, J.,Ohmagari, N.,Shin, D.,Diaz, G.,Asperges, E.,Castagna, A.,Nicastri, E.(2020).Compassionate use of remdesivir for patients with severe Covid-19.New England Journal of Medicine
  33. Gu, JY,Han, B,Wang, J(2020).COVID-19: gastrointestinal manifestations and potential fecal-oral transmission.Gastroenterology
  34. Guan, WJ,Ni, ZY,Hu, Y,Liang, WH,Ou, CQ,He, JX,Liu, L,Shan, H,Lei, CL,Hui, DSC,Du, B,Li, LJ,Zeng, G,Yuen, KY,Chen, RC,Tang, CL,Wang, T,Chen, PY,Xiang, J,Li, SY,Wang, JL,Liang, ZJ,Peng, YX,Wei, L,Liu, Y,Hu, YH,Peng, P,Wang, JM,Liu, JY,Chen, Z,Li, G,Zheng, ZJ,Qiu, SQ,Luo, J,Ye, CJ,Zhu, SY,Zhong, NS(2020).Clinical characteristics of coronavirus disease 2019 in China.New England journal of medicine,382(18),1708.
  35. Holshue, M. L.,DeBolt, C.,Lindquist, S.,Lofy, K. H.,Wiesman, J.,Bruce, H.,Diaz, G.(2020).Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States.N Engl J Med.,382(10),929-936.
  36. Huang, C.,Wang, Y.,Li, X.,Ren, L.,Zhao, J.,Hu, Y.,Cheng, Z.(2020).Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.The lancet,395(10223),497-506.
  37. Hung, I. FN,Lung, KC,Tso, EYK,Liu, R,Chung, TWH,Chu, MY,Shum, HP,Yuen, KW(2020).Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.The Lancet
  38. Jacobs, M.,Rodger, A.,Bell, D. J.,Bhagani, S.,Cropley, I.,Filipe, A.,Johannessen, I.(2016).Late Ebola virus relapse causing meningoencephalitis: a case report.The Lancet,388(10043),498-503.
  39. Jin, X,Lian, JS,Hu, JH,Gao, J,Zheng, L,Zhang, YM,Hao, SR,Jia, HY,Cai, H,Zhang, X L,Yu, GD,Xu, K, J,Wang, XY,Gu, JQ,Zhang, SY,Ye, CY,Jin, CL,Lu, YF,Yu, X,Yu, X, P,Huang, JR,Xu, KL,Ni, Q,Yu, CB,Zhu, B,Li, YT,Liu, J,Zhao, H,Zhang, X,Yu, L,Guo, YZ,Su, JW,Tao, JJ,Lang, GJ,Wu, XX,Wu, WR,Qv, TT,Xiang, DR,Yi, P,Shi, D,Chen, Y,Ren, Y,Qiu, YQ,Li, LJ,Sheng, J,Yang, Y(2020).Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.Gut,0,1-8.
  40. Kalil, AC(2020).Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics.JAMA
  41. Klok, FA,Kruip, MJHA,Van der Meer, NJM,Arbous, MS,Gommers, DAMPJ,Kant, KM,Kant, KM,Kaptein, FHJ,Van Paassen,Stals, MAM,Huisman, MV,Endeman, H(2020).Incidence of thrombotic complications in critically ill ICU patients with COVID-19.Thrombosis Research
  42. Kolivras, A,Dehavay, F,Delplace, D,Feoli, F,Meiers, I,Milone, L,Olemans, C,Sass, U,Theunis, A,Thompson, CT,Van De Borne, L,Richert, B(2020).Coronavirus (COVID-19) infection-induced chilblains: A case report with histopathologic findings.JAAD Case Rep
  43. Kujawski, S. A.,Wong, K. K.,Collins, J. P.,Epstein, L.,Killerby, M. E.,Midgley, C. M.,Anderson, K. N.(2020).,未出版
  44. Lechien, JR,Chiesa-Estomba, CM,De Siati, DR,Horoi, M,Le Bon, SD,Rodriguez, A,Dequanter, D,Blecic, S,El Afia, F,Distinguin, L,Chekkoury-Idrissi, Y,Hans, S,Delgado, IL,Calvo-Henriquez, C,Lavigne, P,Falanga, C,Barillari, MR,Cammaroto, G,Khalife, M,Leich, P,Souchay, C,Rossi, C,Journe, F,Hsieh, J,Edjlali, M,Carlier, R,Ris, L,Lovato, A,De Filippis, C,Coppee, F,Fakhry, N,Ayad, T,Saussez, S(2020).Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.Eur Arch Otorhinolaryngol
  45. Li, L,Yang, D,Li, J,Niu, L,Chen, Y,Zhao, X,Oduro, PK,Wei, C,Xu, Z,Wang, Q,Li, Y(2020).Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation.BMC Complementary Medicine and Therapies,20(112),1-15.
  46. Li, Q,Guan, X,Wu, P,Wang, X,Zhou, L,Tong, Y,Ren, R,Leung, KSM,Lau, EHY,Wong, JY,Xing, X,Xiang, N,Wu, Y,Li, C,Chen, Q,Li, D,Liu, T,Zhao, J,Liu, M,Tu, W,Chen, C,Jin, L,Yang, R,Wang, Q,Zhou, S,Wang, R,Liu, H,Luo, Y,Liu, Y,Shao, G,Li, H,Tao, Z,Yang, Y,Deng, Z,Liu, B,Ma, Z,Zhang, Y,Shi, G,Lam, TTY,Wu, JT,Gao, GF,Cowling, BJ,Yang, B,Leung, GM,Feng, Z(2020).Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.New England Journal of Medicine,382(13),1199.
  47. Li, RF,Hou, YL,Huang, JC,Pan, WQ,Ma, QH,Shi, YX,Li, CF,Zhao, J,Jia, ZH,Jiang, HM,Zheng, K,Huang, SX,Dai, J,Li, XB,Hou, XT,Wang, L,Zhong, NS,Yang, ZF(2020).Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).Pharmacological research,156,104761.
  48. Lippi, G,Plebani, M,Henry, BM(2020).Thrombocytopenia is associated with severe corona virus disease 2019 (COVID-19) infections: A meta-analysis.Clinica Chimica Acta,506,145-148.
  49. Liu, HW,Yan, Y,Pang, PF,Mao, JJ,Hu, XJ,Li, D,Zhou, B,Shan, H(2019).Angong Niuhuang Pill as adjuvant therapy for treating acute cerebral infarction and intracerebral hemorrhage: A meta-analysis of randomized controlled trials.Journal of ethnopharmacology,237,307-313.
  50. Lu, J,Yan, J,Yan, J,Zhang, L,Chen,M,Chen, Q,Li, P(2020).Network pharmacology based research into the effect and mechanism of Xijiao Dihuang decoction against sepsis.Biomedicine & Pharmacotherapy,122,109777.
  51. Lu, R,Zhao, X,Li, J,Niu, P,Yang, B,Wu, H,Wang, W,Song, H,Huang, B,Zhu, N,Bi, Y,Ma, X,Zhan, F,Wang, L,Hu, T,Zhou, H,Hu, Z,Zhou, W,Zhao, L,Chen, J,Meng, Y,Wang, J,Lin, Y,Yuan, J,Xie, Z,Ma, J,Liu, WJ,Wang, D,Xu, W,Holmes, EC,Gao, GF,Wu, G,Chen, W,Shi, W,Tan, W(2020).Genomic characterisation and epidemiology of 2019 novel coronavirus.Lancet,395(10224),565.
  52. Manalo, IF,Smith, MK,Cheeley, J,Jacobs, R(2020).A Dermatologic Manifestation of COVID-19: Transient Livedo Reticularis.J Am Acad Dermatol
  53. Menter, T,Haslbauer, JD,Nienhold,R,Savic,S,Hopfer, H,Deigendesch, N,Bassetti, S(2020).Post mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction.Histopathology
  54. Morra, M. E.,Van Thanh, L.,Kamel, M. G.,Ghazy, A. A.,Altibi, A. M.,Dat, L. M.,Elabd, S. S.(2018).Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis.Rev Med Virol,28(3),e1977.
  55. Oxley, TJ,Mocco, J,Majidi, S,Kellner, CP,Shoirah, H,Singh, IP,De Leacy, RA,Shigematsu, T,Ladner, TR,Yaeger, KA,Skliut, M,Weinberger, J,Dangayach, NS,Bederson, JB,Tuhrim, S,Fifi, JT(2020).Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.The New England journal of medicine
  56. Pan, F,Ye, T,Sun, P,Gui, S,Liang, B,Li, L,Zheng, D,Wang, J,Hesketh, RL,Yang, L,Zheng, C(2020).Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia.Radiology
  57. Pan, L,Mu, M,Ren, HG,Yang, P,Sun, Y,Wang, R,Yan, J,Li, P,Hu, B,Wang, J,Hu, C,Jin, Y,Niu, X,Ping, R,Du, Y,Li, T,Xu, G,Hu, Q,Tu, L(2020).Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study.American Journal of Gastroenterology
  58. Recalcati, S(2020).Cutaneous manifestations in COVID 19: a first perspective.J Eur Acad Dermatol Venereol
  59. Ren, JL,Zhang, AH,Wang, XJ(2020).Traditional Chinese medicine for COVID-19 treatment.Pharmacological research,155,104743.
  60. Richardson, S,Hirsch, JS,Narasimhan, M,Crawford, JM,McGinn, T,Davidson, KW,Northwell COVID-19 Research Consortium,Barnaby, DP,Becker, LB,Chelico, JD,Cohen, SL,Cookingham, J,Coppa, K,Diefenbach, MA,Dominello, AJ,Duer-Hefele, J,Falzon, L,Gitlin, J,Hajizadeh, N,Harvin, TG,Hirschwerk, DA,Kim, EJ,Kozel, ZM,Marrast, LM,Mogavero, JN,Osorio, GA,Qiu, M,Zanos, TP(2020).Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.JAMA
  61. Sanders, J. M.,Monogue, M. L.,Jodlowski, T. Z.,Cutrell, J. B(2020).Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review.Jama
  62. Savarino, A,Boelaert, JR,Cassone, A,Majori, G,Cauda, R(2003).Effects of chloroquine on viral infections: an old drug against today’s diseases?.Lancet Infect Dis,3(11),722-727.
  63. Sheahan, T. P.,Sims, A. C.,Leist, S. R.,Schäfer, A.,Won, J.,Brown, A. J.,Spahn, J. E.(2020).Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.Nature Communications,11(1),1-14.
  64. Shi, H,Han, X,Jiang, N,Cao, Y,Alwalid, O,Gu, J,Fan, Y,Zheng, C(2020).Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.The Lancet Infectious Diseases,20(4),425.
  65. Siegel, D.,Hui, H. C.,Doerffler, E.,Clarke, M. O.,Chun, K.,Zhang, L.,Wang, Q.(2017).Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2,1-f] [triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses.J Med Chem,60(5),1648-1661.
  66. Spinato, G,Fabbris, C,Polesel, J,Cazzador, D,Borsetto, D,Hopkins, C,Boscolo-Rizzo, P(2020).Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection.JAMA
  67. Stockman, LJ,Bellamy, R,Garner, P(2006).SARS: systematic review of treatment effects.PLoS Med,3(9),e343.
  68. Terpos, E,Ntanasis Stathopoulos, I,Elalamy, I,Kastritis, E,Sergentanis, TN,Politou, M,Psaltopoulou, T,Gerotziafas, G,Dimopoulos, MA(2020).Hematological findings and complications of COVID 19.American Journal of Hematology
  69. Totura, A. L.,Bavari, S.(2019).Broad-spectrum coronavirus antiviral drug discovery.Expert opinion on drug discovery,14(4),397-412.
  70. U.S. Food and Drug Administration: Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment (2020.05.01); https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
  71. van Doremalen, N,Bushmaker, T,Morris, DH,Holbrook, MG,Gamble, A,Williamson, BN,Tamin, A,Harcourt, JL,Thornburg, NJ,Gerber, SI,Lloyd-Smith, JO,de Wit, E,Munster, VJ(2020).Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1.N Engl J Med.,382(16),1564.
  72. Varga, Z,Flammer, AJ,Steiger, P,Haberecker, M,Andermatt, R,Zinkernagel, AS,Mehra, MR,Schuepbach, RA,Ruschitzka, F,Moch, H(2020).Endothelial cell infection and endotheliitis in COVID-19.The Lancet
  73. Wang, D,Hu, B,Hu, C,Zhu, F,Liu, X,Zhang, J,Wang, B,Xiang, H,Cheng, Z,Xiong, Y,Zhao, Y,Li, Y,Wang, X,Peng, Z(2020).Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.Jama,323(11),1061-1069.
  74. Wang, GH,Lan, R,Zhen, XD,Zhang, W,Xiang, J,Cai, DF(2014).An-Gong-Niu-Huang Wan protects against cerebral ischemia induced apoptosis in rats: up-regulation of Bcl-2 and down-regulation of Bax and caspase-3.Journal of ethnopharmacology,154,156-162.
  75. Wang, M.,Cao, R.,Zhang, L.,Yang, X.,Liu, J.,Xu, M.,Xiao, G.(2020).Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.Cell research,30(3),269-271.
  76. World Health Organization: Coronavirus disease (COVID-19) Situation Report -116 (2020.05.15); https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200515-covid-19-sitrep-116.pdf?sfvrsn=8dd60956_2
  77. World Health Organization: Novel Coronavirus(2019-nCoV) Situation Report-22 (2020.02.11); https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2
  78. Wu, Z,McGoogan, JM(2020).Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention.Jama,323(13),1239-1242.
  79. Xu, J,Zhang, Y(2020).Traditional Chinese Medicine treatment of COVID-19.Complementary Therapies in Clinical Practice,39,101165.
  80. Yang, Y,Islam, M, S,Wang, J,Li, Y,Chen, X(2020).Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective.International journal of biological sciences,16(10),1708-1717.
  81. Yao, X.,Ye, F.,Zhang, M.,Cui, C.,Huang, B.,Niu, P.,Zhan, S(2020).In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Clinical Infectious Diseases
  82. Zarychanski, R,Houston, DS(2017).Assessing thrombocytopenia in the intensive care unit: the past, present, and future.Hematology Am Soc Hematol Educ Program,1,660-666.
  83. Zhou, D,Dai, SM,Tong, Q(2020).COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.Journal of Antimicrobial Chemotherapy,dkaa114.
  84. Zhou, P,Yang, XL,Wang, XG,Hu, B,Zhang, L,Zhang, W,Si, HR,Zhu, Y,Li, B,Huang, CL,Chen, HD,Chen, J,Luo, Y,Guo, H,Jiang, RD,Liu, MQ,Chen, Y,Shen, XR,Wang, X,Zheng, XS,Zhao, K,Chen, QJ,Deng, F,Liu, LL,Yan, B,Zhan, FX,Wang, YY,Xiao, GF,Shi, ZL(2020).A pneumonia outbreak associated with a new coronavirus of probable bat origin.Nature,579(7798),270.
  85. Zhu, N,Zhang, D,Wang, W,Li, X,Yang, B,Song, J,Zhao, X,Huang, B,Shi, W,Lu, R,Niu, P,Zhan, F,Ma, X,Wang, D,Xu, W,Wu, G,Gao, GF,Tan, W(2020).A novel coronavirus from patients with pneumonia in China, 2019.N Engl J Med.,382(8),727.
  86. 中國國家衛生健康委員會：關於印發新型冠狀病毒肺炎診療方案（試行第七版）的通知（2020/03/03）；http://big5.www.gov.cn/gate/big5/www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm。
  87. 方鵬程(2013).孫真人備急千金要方.台北:台北商務印書館.
  88. 王洪圖(2004).黃帝內經素問白話解.北京:人民衛生出版社.
  89. 王剛,金勁松(2020)。新型冠狀病毒肺炎中醫認識初探。天津中醫藥，37(3)，247-250。
  90. 任璽,文小敏,洪冰,廖瑩峰,馬文,湯亞忻(2012)。三仁湯對脾胃濕熱證大鼠血清 Th1/Th2 細胞因子的影響。南方醫科大學學報，32(2)，181-184。
  91. 朱願超,譚玲,劉蕾,李可欣,齊文淵,胡欣(2020)。新型冠狀病毒肺炎與傳染性非典型肺炎特點及藥物治療的對比分析。臨床藥物治療雜誌，18(2)，15-23。
  92. 何黎黎,龔普陽,封玥,鄒薇,王恩龍,顧健(2020)。中藥在抗新型冠狀病毒肺炎（COVID-19）引起的細胞因子風暴中的應用分析。中草藥，6(2)，1-11。
  93. 呂明進,蔡金川,吳訓旺,游智勝(2011).中醫溫病學.台中:中國醫藥大學.
  94. 呂睿冰,王文菊,李欣(2020)。中藥連花清瘟治療新型冠狀病毒肺炎疑似病例 63例臨床觀察。中醫雜誌，61(8)，655-659。
  95. 李曉宇,謝立科,郝曉鳳,馬克信,羅金花(2020)。從中醫疫病角度淺談對新型冠狀病毒肺炎的認識及其眼部表現和防治。世界中醫藥，2(7)，155-158。
  96. 宗陽,丁美林,賈可可,馬世堂,居文政(2020)。基於網絡藥理學和分子對接法探尋達原飲治療新型冠狀病毒肺炎（COVID-19）活性化合物的研究。中草藥，51(4)，2。
  97. 金銳,王宇光(2020)。基於湯液經法圖的新型冠狀病毒肺炎臨床各期中藥治療複方的配伍原理及加減原則研究。中南藥學，18(3)，1-5。
  98. 姚開濤,劉明瑜,李欣,黃繼漢,蔡宏斌(2020)。中藥連花清瘟治療新型冠狀病毒肺炎的回顧性臨床分析。中國實驗方劑學雜誌，26(3)，1-7。
  99. 夏文廣,安長青,鄭嬋娟,張繼先,黃敏,王喻,張伯禮(2020)。中西醫結合治療新型冠狀病毒肺炎 34 例臨床研究。中醫雜誌，61(5)，375-381。
  100. 孫春霞,曹振東,畢婉蓉,施青(2020)。中醫藥防治新型冠狀病毒肺炎探討。國際全科醫學，1(1)，32-39。
  101. 張宇,梁志鋒,徐象輝(2019)。犀角地黃湯聯合西藥對膿毒症凝血功能障礙患者臨床療效、凝血指標及預後的影響。中國醫學創新，16，33。
  102. 莊鶴麟,徐願,宋乃光(2009)。三仁湯治療感染性疾病的研究。吉林中醫藥，29(11)，985-986。
  103. 陳懷宇,鄭則敏,唐雪華,林名瑞,何紹吾,李瑋(2020)。犀角地黃湯對膿毒癥大鼠脾組織 NF-κB 信號通路相關基因表達的影響。當代醫學，8，4。
  104. 彭濤,賈魯棟(2020)。新型冠狀病毒所致免疫性肺損害中醫治療的一些思考。經典中醫研究，2，1-6。
  105. 楊倩,孫勤國,江波,徐鴻婕,羅蒙,謝萍,黃威,叢澤偉(2020)。中西醫結合治療新型冠狀病毒肺炎重癥患者的回顧性臨床研究。中草藥，51(8)，2050-2054。
  106. 趙靜,田賽賽,楊健,劉劍鋒,張衛東(2020)。清肺排毒湯治療新型冠狀病毒肺炎機制的網絡藥理學探討。中草藥，51(4)，829-835。
  107. 劉柳毅,劉麗君,周本傑(2020)。中醫藥對新型冠狀病毒肺炎的認識與防治。中國藥業，29(5)，23-26。
  108. 劉運磊,景蓉,惠彩霞,任鳳霞,萬曉燕,李元軍,陳延平,李春豔,毛婭,李笑梅(2020)。基於痰濕毒瘀論對新型冠狀病毒肺炎的中醫治療。延安大學學報（醫學科學版），18(1)，6-9。
  109. 劉歡葦,張舒,鄧迪,毛欽,郭銳,吳珺,郝鈺(2019)。犀角地黃湯合銀翹散影響 PKC-SSeCKS 介導的 F-actin 變構抑制流感病毒誘導的 PMVEC 通透性增加。中國免疫學雜誌，35(24)，2975。
  110. 薛伯壽,姚魁武,薛燕星(2020)。清肺排毒湯快速有效治療新型冠狀病毒肺炎的中醫理論分析。中醫雜誌，61(6)，461-462。
被引用次数
  1. 龔彥穎,陳昕元,張凱惟(2023)。中醫治療肝癌併新冠後腹瀉納差之病例報告。台北市中醫醫學雜誌，29(2)，61-74。
  2. 賴冠文,陳靜儀,陳珮綺(2022)。戴口罩是否可以降低嚴重特殊傳染性肺炎傳播。彰化護理，29(2)，104-116。
  3. 劉虹伶,李聰界,巫孟萱(2021)。探討新型冠狀病毒肺炎指引與常用中醫處方。中醫內科醫學雜誌，19(2)，1-12。
  4. (2024)。以中醫角度探討時疫COVID-19。臺灣中醫醫學雜誌，20(2)，5-22。
print cancel